Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease.

Literature DB >> 11177658

Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease.

Abstract

The importance of platelets in coronary artery disease has been better elucidated in the past 20 years with the continued understanding of their role in the development of the atherosclerotic lesion and acute coronary syndromes. The most recent therapeutic efforts have focused on blockade of the platelet glycoprotein IIb/IIIa receptor, which represents the final common pathway to platelet aggregation and arterial thrombus formation. This manuscript summarizes platelet function and pathophysiology, currently available glycoprotein IIb/IIIa inhibitors, and the important clinical trials with this new class of drugs.

Entities: Disease

Mesh：

Substances：

Year: 2001 PMID： 11177658 DOI： 10.1007/s11883-001-0050-7

Source DB: PubMed Journal: Curr Atheroscler Rep ISSN： 1523-3804 Impact factor: 5.113

48 in total

Review 1. The biology of glycoprotein IIb-IIIa.

Authors: E F Plow; T Byzova
Journal: Coron Artery Dis Date: 1999-12 Impact factor: 1.439

2. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Authors: E J Topol; J J Ferguson; H F Weisman; J E Tcheng; S G Ellis; N S Kleiman; R J Ivanhoe; A L Wang; D P Miller; K M Anderson; R M Califf
Journal: JAMA Date: 1997-08-13 Impact factor: 56.272

6. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors:
Journal: Lancet Date: 1997-05-17 Impact factor: 79.321

7. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.

Authors:
Journal: Lancet Date: 2000-01-29 Impact factor: 79.321

8. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors:
Journal: N Engl J Med Date: 1993-11-25 Impact factor: 91.245

9. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

Authors:
Journal: J Am Coll Cardiol Date: 1998-12 Impact factor: 24.094

10. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors:
Journal: Lancet Date: 1998-07-11 Impact factor: 79.321

2 in total

1. Use of glycoprotein IIb-IIIa inhibitor for a thromboembolic complication during Guglielmi detachable coil treatment of an acutely ruptured aneurysm.

Authors: P P Ng; C C Phatouros; M S Khangure
Journal: AJNR Am J Neuroradiol Date: 2001-10 Impact factor: 3.825

2. An α_IIbβ₃- and phosphatidylserine (PS)-binding recombinant fusion protein promotes PS-dependent anticoagulation and integrin-dependent antithrombosis.

Authors: Jian Jing; Yanna Sun
Journal: J Biol Chem Date: 2019-02-25 Impact factor: 5.157